Pharmaceutical Companies in the US

Overview

The US pharmaceutical market spans global branded drug manufacturers, generic producers, biotechs with active clinical pipelines, and contract research and manufacturing organizations — each operating under distinct regulatory frameworks and procurement structures. This audience covers 68,000+ US pharmaceutical companies with sub-category classification, therapeutic area focus, funding data, and verified executive and scientific leadership contacts.

What's Included

• Company Identity: Verified name, primary domain, and US headquarters
• Pharma Category: Branded, generic, biotech, specialty pharma, CRO, or CDMO
• Financials: Revenue estimates and employee count
• Funding Profile: Stage, total raised, and most recent round date (for private companies)
• Therapeutic Area: Oncology, immunology, CNS, cardiovascular, rare disease, or other therapeutic focus where available
• Leadership Contacts: Verified email and phone for CEO, CFO, Chief Medical Officer, VP of R&D, and VP of Clinical Operations

Use Cases

Pharma Technology and Software Sales

Clinical data management, regulatory affairs, ERP, and supply chain software vendors should use pharma category and company size to identify the right buyer and positioning. A global branded pharma company and a clinical-stage biotech have entirely different software maturity levels and procurement processes.

Clinical Research and Outsourcing Services

CROs, site management organizations, and clinical technology vendors can use therapeutic area and funding stage to identify pharma companies with active or near-term clinical development programs. Companies with recent funding and early-stage pipelines represent the highest-volume buyers of outsourced research services.

Regulatory and Compliance Solutions

Regulatory consultancies, pharmacovigilance platforms, and quality management systems can filter by pharma category to identify companies navigating specific FDA pathways and compliance requirements. Branded and specialty pharma companies have significantly more complex regulatory needs than generic manufacturers.

Investor Deal Sourcing

Life sciences investors can filter by therapeutic area, funding stage, and pharma category to surface companies that fit specific portfolio mandates. Therapeutic area classification is essential for fund specialization — an oncology-focused fund and a rare disease fund are evaluating entirely different sets of companies.